visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study |
Data: | 2019 |
Resum: | Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1. 23; 95% CI = 1. 01-1. 48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1. 28; 95% CI = 1. 02-1. 60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1. 21; 95% CI = 1. 00-1. 47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies. |
Ajuts: | Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR-1085 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-756 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR-733 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-647 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-850 Instituto de Salud Carlos III FEDER/PI08-1770 Instituto de Salud Carlos III FEDER/PI08-1359 Instituto de Salud Carlos III FEDER/PI08-0533 Instituto de Salud Carlos III FEDER/PS09-00773 Instituto de Salud Carlos III FEDER/PS09-01286 Instituto de Salud Carlos III FEDER/PS09-01903 Instituto de Salud Carlos III FEDER/PS09-02078 Instituto de Salud Carlos III FEDER/PS09-01662 Instituto de Salud Carlos III FEDER/PI11-01403 Instituto de Salud Carlos III FEDER/PI11-01889 Instituto de Salud Carlos III FEDER/PI11-00226 Instituto de Salud Carlos III FEDER/ PI11-01810 Instituto de Salud Carlos III FEDER/PI11-02213 Instituto de Salud Carlos III FEDER/PI12-00488 Instituto de Salud Carlos III FEDER/PI12-00265 Instituto de Salud Carlos III FEDER/PI12-01270 Instituto de Salud Carlos III FEDER/PI12-00715 Instituto de Salud Carlos III FEDER/PI12-00150 Instituto de Salud Carlos III FEDER/PI14-01219 Instituto de Salud Carlos III FEDER/PI14-0613 Instituto de Salud Carlos III FEDER/PI15-00069 Instituto de Salud Carlos III FEDER/PI15-00914 Instituto de Salud Carlos III FEDER/PI15-01032 Instituto de Salud Carlos III FEDER/PI11-01810 Instituto de Salud Carlos III FEDER/PIE16-00049 Instituto de Salud Carlos III FEDER/PI17-01179 Instituto de Salud Carlos III FEDER/PI14-01219 Instituto de Salud Carlos III FEDER/PI11-02213 Instituto de Salud Carlos III RD12-0036-0036 |
Nota: | Altres ajuts: This work was partially funded by the public grants from the Catalan Government and European Regional Development Fund-ERDF, by the "Accion Transversal del Cancer", approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER, by the Fundación Marqués de Valdecilla (API 10/09), by the Red Temática de Investigación del Cáncer (RTICC), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government-Agency for Management of University and Research Grants . ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Alkylphenolic compounds ; Alkylphenols ; Breast cancer ; Job-exposure matrix ; Occupational exposure ; Prostate cancer |
Publicat a: | Environment International, Vol. 122 (january 2019) , p. 389-399, ISSN 1873-6750 |
11 p, 747.3 KB |